EAST SETAUKET, N.Y., Jan. 7, 2014 /PRNewswire/ -- John S. Kovach, M.D., President and CEO, Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board.
"We are extremely pleased that Dr. Von Hoff has joined the Lixte Scientific Advisory Board. Dr. Von Hoff is internationally recognized as a leader in the pre-clinical and clinical development of new anti-cancer drugs. He and his colleagues were instrumental in the advancement of many anti-cancer drugs now used routinely in cancer care. We very much look forward to Dr. Von Hoff's suggestions regarding the most efficient clinical development of our proprietary anti-cancer compounds," says Dr. Kovach.
Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute), Phoenix, AZ. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute and holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.
Dr. Von Hoff served on the National Cancer Advisory Board from 2004-2010. He is a past President of the American Association of Cancer Research (AACR), Fellow of the American College of Physicians (FACP), and a member and past board member of the American Society of Clinical Oncology (ASCO). He is a founder of ILEX™Oncology, Inc., subsequently acquired by Genzyme. Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs: The Journal of New Anti-Cancer Agents and Editor-in-Chief of Molecular Cancer Therapeutics.
Dr. Von Hoff has published more than 600 papers and 135 book chapters. He received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care.
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company, using biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development which the company believes have broad therapeutic potential not only for cancer but for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is in a Phase I cancer trial at two NCI designated Comprehensive Cancer Centers (see ClinicalTrials.gov: Identifier NCTO1837667). For further discussion of the Lixte pipeline, go to: http://lixte.com/Nature_Biotechnology_2013_Lixte_Ad.pdf
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Annual Report on Form 10Q for September 30, 2013.
For additional information, please see: www.lixte.com
SOURCE Lixte Biotechnology Holdings, Inc.